Leadership
-
Benjamin Orsburn
Ben Orsburn received his Ph.D. from Virginia Tech for using mass spectrometry to study the cell walls of bacterial pathogens. He performed two postdoctoral fellowships, at the Johns Hopkins University and the…...
-
Qing Wang
Dr. Wang graduated from Johns Hopkins University with a PhD, supervised by Dr. Bert Vogelstein at the School of Medicine, and an MHS in Biostatistics, supervised by Dr. Rafael Irizarry…...
-
Ming Zhang
Ming Zhang obtained her Bachelor’s degree and her PhD degree in Department of Molecular Biology and Biochemistry from Nankai University with a research focus on disease-causing gene identification and signaling…...
-
Liang Zhao
Liang Zhao received his Ph.D. degree of Analytical Chemistry in 2011 from University of the Pacific. He then continued his research in analytical chemistry by pursuing a post-doctoral training in…...
Our Scientists
In clinical proteomics, we invented the 1st proteomics-based platform to quantify mutant proteins from cancer patient body fluids in 2010, and we established the 1st clinical proteomics diagnostics platform for ovarian cancers with a zero false positive ratio, and most recently, we invented the 1st neoantigen quantification platform for highly personalized cancer therapeutics. In clinical genomics, we invented and patented the world’s only dual RNA probes for capture-based targeted sequencing for ultra-rare mutation calling (even compatible with tough and damaged clinical samples), and publications from our genomics scientists have been cited for over 8,000 times, numerous novel cancer driver genes and NGS-based early cancer diagnostic methods were reported by us. Now, we are doing something even more exciting … …
- Qing Wang
- Liang Zhao
- Benjamin Orsburn
- Yuri Laguna Terai
- Jayden Kunwar
- Christopher Adewole
- Parth Parikh
- Hui Zhang
- Ming Zhang
- Smarika Jay
- Hamza Umar
- Raj Purohit
- Stanley Wang
